Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Dr Joshua Ko

Dr Joshua Ko

Hong Kong Baptist University
Hong Kong

Title: AST is a novel anti-carcinogenic regimen against gastrointestinal cancer development with unique molecular targets

Biography

Biography: Dr Joshua Ko

Abstract

The dried root of Astragalus membranaceus (Radix Astragali) has a long history of medicinal use in Traditional Chinese Medicine as an immunomodulating agent to ameliorate the side effects of cytotoxic antineoplastic drugs. In recent years, we have demonstrated that total Astragalus saponins (AST) caused significant growth inhibition and pro-apoptotic effects in human colon adenocarcinoma cells and tumor xenograft, which synergistically worked with conventional chemotherapeutic drug combo while alleviating the associated drug-induced toxicity (Carcinogenesis 28:1347-55, 2007). Its mechanism of action involved phase-specific cell cycle arrest and exhibited anti-carcinogenic activity in 8 different human cancer cell lines, confirming its universal chemotherapeutic property (Int. J. Cancer 125:1082-1091, 2009). By using customized cDNA array, we have revealed that AST increased the gene expression of proangiogenic factors and downregulated the expression of proangiogenic molecules. Besides, genes that are relevant to metastasis and invasion including matrix metallopeptidases and the metastasis associated genes mta1 and Twist were also downregulated. Contribution of AST to the modulation of angiogenesis, tumor invasiveness and metastasis was further confirmed. The anti-metastatic potential of AST could be demonstrated by employing a modified liver metastasis model. We have identified NSAID-activated gene (NAG-1) as a molecular target of AST, which could be correlated with modulation of the upstream PI3K-AST signaling pathway. Other than colorectal cancer cells, AST has also exhibited promising anti-carcinogenic effects in hepatocarcinoma cells by down-regulating expression of the liver tumor marker α-fetoprotein, as well as promoting pro-apoptotic activity through modulation of an ERK-independent NF-B signaling pathway. Glucose-regulated proteins (GRP) are induced in the cancer microenvironment to promote tumor survival, metastasis and drug resistance. Our findings exemplify that calpains, in particular calpain II, played a permissive role in the modulation of GRP78 and consequent regulation of ER stress-induced apoptosis brought forth by AST. Data obtained from these studies could facilitate future establishment of AST as an effective target-specific chemotherapeutic and adjuvant agent in treating human colorectal and liver cancers, with unique molecular targets such as NAG-1 and calpain.